-
Posted by
Two Blokes Jul 10 -
Filed in
Stock
-
5 views
Centene's stock plunged after withdrawing 2025 guidance due to higher medical costs, but the selloff appears to be a capitulation event. The stock is deeply oversold, trading at just 10x reduced 2025 earnings, with a strong balance sheet and potential for a sharp rebound in 2026-2027. Challenges include Medicaid cuts and higher-risk policyholders, but corrective pricing actions and sector defensiveness in a recession offer upside.
